AVAILABILITY OF ERENUMAB FOR MIGRAINE SUFFERERS

Motion Text

That this House disagrees with the decision made by the National Institute for Care Excellence to reject the migraine prevention drug Erenumab on the NHS in England, Wales and Northern Ireland; is disappointed by the reasoning that the drug was not cost-effective; believes that the health and well-being of migraine sufferers must take precedence over cost margins; and calls on the Government to overturn that decision in line with the Scottish Medicines Consortium to ensure that all migraine sufferers in the UK are given equal and free access to this promising new treatment.